Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The Minnesota Living with Heart Failure (LIhiFE) questionnaire was developed to systematically and comprehensively assess the patient's perceptions of the effects of heart failure, and its treatment on his or her daily life.1 A valid measure of therapeutic response should be responsive to medications known to benefit patients with heart failure and be insensitive to the effects of placebo. In addition, a valid measure would indicate that patients with overt heart failure have more impairment than do those with left ventricular dysfunction who do not need medications for heart failure. We previously showed that this questionnaire was sensitive to the effects of pimobendan, an inotropic agent with vasodilator properties, and was insensitive to placebo in patients with moderate-to-severe heart failure.2,3 This report demonstrates the questionnaire's responsiveness to a converting enzyme inhibitor and confirms its insensitivity to placebo.
Bibliographical noteFunding Information:
From the Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware Street SE., Minneapolis, Minnesota 55455. The Studies of Left Ventricular Dysfunction (SOLVD) were funded by the National Heart, Lung, and Blood Institute, Bethesda, Maryland, with a contribution from Merck Sharp and Dohme Pharmaceutical Company, West Point, Pennsylvania. Manuscript received July 14, 1992; revised manuscript received and accepted September 22, 1992.
Copyright 2014 Elsevier B.V., All rights reserved.